Literature DB >> 12061529

Effects of the calcium channel antagonist amlodipine in cats with surgically induced hypertensive renal insufficiency.

Sheerin Mathur1, Harriet Syme, Cathy A Brown, Jonathan Elliot, Phillip A Moore, Melvin A Newell, John S Munday, Leslie M Cartier, Suzanne E Sheldon, Scott A Brown.   

Abstract

OBJECTIVE: To determine whether amlodipine besylate decreases systemic arterial blood pressure (BP) and reduces the prevalence of complications in cats with induced hypertensive renal insufficiency. ANIMALS: 20 cats with partial nephrectomy. PROCEDURE: Following reduction in renal mass, 10 cats were administered 0.25 mg of amlodipine/kg, PO, q 24 h (group A). Ten cats served as a control group (group C). Systolic BP (SBP), diastolic BP (DBP), and mean BP (MBP), physical activity, and pulse rate were measured continuously for 36 days by use of radiotelemetric devices.
RESULTS: Compared with values for clinically normal cats, SBP, DBP, and MBP were significantly increased in cats of group C. Cats in group A had significant reductions in SBP, DBP, and MBP, compared with values for cats in group C. Albuminuria but not urine protein-to-creatinine ratio was significantly correlated (R2 = 0.317) with SBP in hypertensive cats. Prevalence of ocular lesions attributable to systemic hypertension in group C (7 cats) was greater than that observed in group A (2). Two cats in group C were euthanatized on day 16 because of nuerologic complications attributed to systemic hypertension. One normotensive cat in group A was euthanatized because of purulent enteritis of unknown cause on day 27. CONCLUSIONS AND CLINICAL RELEVANCE: Amlodipine had an antihypertensive effect in cats with coexistent systemic hypertension and renal insufficiency. Its use may improve the prognosis for cats with systemic hypertension by decreasing the risk of ocular injury or neurologic complications induced by high BP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12061529     DOI: 10.2460/ajvr.2002.63.833

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  6 in total

1.  Randomized placebo-controlled clinical trial of a chewable formulation of amlodipine for the treatment of hypertension in client-owned cats.

Authors:  M Huhtinen; G Derré; H J Renoldi; M Rinkinen; K Adler; J Aspegrén; C Zemirline; J Elliott
Journal:  J Vet Intern Med       Date:  2015-04-09       Impact factor: 3.333

2.  Survival after diagnosis of hypertension in cats attending primary care practice in the United Kingdom.

Authors:  Megan Conroy; Yu-Mei Chang; Dave Brodbelt; Jonathan Elliott
Journal:  J Vet Intern Med       Date:  2018-10-13       Impact factor: 3.333

3.  Plasma renin activity and aldosterone concentrations in hypertensive cats with and without azotemia and in response to treatment with amlodipine besylate.

Authors:  R E Jepson; H M Syme; J Elliott
Journal:  J Vet Intern Med       Date:  2013-11-13       Impact factor: 3.333

4.  ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats.

Authors:  Mark J Acierno; Scott Brown; Amanda E Coleman; Rosanne E Jepson; Mark Papich; Rebecca L Stepien; Harriet M Syme
Journal:  J Vet Intern Med       Date:  2018-10-24       Impact factor: 3.333

Review 5.  The cat with neurological manifestations of systemic disease. Key conditions impacting on the CNS.

Authors:  Marc Kent
Journal:  J Feline Med Surg       Date:  2009-05       Impact factor: 2.015

6.  Hypertension, retinopathy, and acute kidney injury in dogs: A prospective study.

Authors:  Laura Pearl Cole; Rosanne Jepson; Charlotte Dawson; Karen Humm
Journal:  J Vet Intern Med       Date:  2020-07-17       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.